Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development.
Antiviral drug development
Microcephaly
Neurological complications
Sexual transmission
Vaccine development
Zika virus (ZIKV)
Journal
Virology
ISSN: 1096-0341
Titre abrégé: Virology
Pays: United States
ID NLM: 0110674
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
31
10
2019
revised:
21
01
2020
accepted:
27
01
2020
pubmed:
15
2
2020
medline:
2
10
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
Zika Virus (ZIKV) is a Flavivirus transmitted primarily via the bite of infected Aedes aegypti mosquitoes. Globally, 87 countries and territories have recorded autochthonous mosquito-borne transmission of ZIKV as at July 2019 and distributed across four of the six WHO Regions. Outbreaks of ZIKV infection peaked in 2016 and declined substantially throughout 2017 and 2018 in the Americas region. There is the likely risk for ZIKV to spread to more countries. There is also the potential for the re-emergence of ZIKV in all places with prior reports of the virus transmission. The current status of ZIKV transmission and spread is, however, a global health threat, and from the aforementioned, has the potential to re-emerge as an epidemic. This review summarizes the past and present spread of ZIKV outbreak-2007-2019, the genome, transmission cycle, clinical manifestations, vaccine and antiviral drug advancement.
Identifiants
pubmed: 32056845
pii: S0042-6822(20)30021-0
doi: 10.1016/j.virol.2020.01.015
pii:
doi:
Substances chimiques
Antiviral Agents
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-42Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no competing interest concerning the publication of this review.